{"nctId":"NCT01304498","briefTitle":"Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)","startDateStruct":{"date":"2011-02-23","type":"ACTUAL"},"conditions":["Human Papillomavirus"],"count":600,"armGroups":[{"label":"V503","type":"EXPERIMENTAL","interventionNames":["Biological: V503"]},{"label":"GARDASIL","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: GARDASIL"]}],"interventions":[{"name":"V503","otherNames":["9vHPV vaccine"]},{"name":"GARDASIL","otherNames":["qHPV vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female from 9 to 15 years old.\n* Good physical health.\n\nExclusion Criteria:\n\n* Known allergy to any vaccine component.\n* History of severe allergic reaction.\n* Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.\n* Pregnant subject.\n* Immunocompromised or immunodeficient subject.\n* Splenectomy.\n* Receipt of medication / vaccine that may interfere with study assessment.\n* Fever\n* History of a positive test for HPV, prior receipt of HPV vaccine or prior participation to HPV trial.\n* Any condition that might interfere with study assessment.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"9 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) to HPV Types 16 and 18","description":"Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6739.5","spread":null},{"groupId":"OG001","value":"6887.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1956.6","spread":null},{"groupId":"OG001","value":"1795.6","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs to HPV Types 6 and 11","description":"Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1679.4","spread":null},{"groupId":"OG001","value":"1565.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1315.6","spread":null},{"groupId":"OG001","value":"1417.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18","description":"Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Adverse Events","description":"An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"93.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Injection-site Adverse Reactions","description":"The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null},{"groupId":"OG001","value":"88.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Systemic Adverse Events","description":"The percentage of participants with one or more systemic adverse events was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"52.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Maximum Oral Temperature ≥37.8°C","description":"The percentage of participants with maximum oral temperature ≥37.8°C was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Serious Adverse Events","description":"A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":299},"commonTop":["Injection-site pain","Injection-site swelling","Injection-site erythema","Headache","Pyrexia"]}}}